Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

Literature DB >> 20368403

In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

Abstract

The in vitro activities of DC-159a against seven species of Mycobacterium were compared with moxifloxacin, gatifloxacin, levofloxacin, and rifampin. DC-159a was the most active compound against quinolone-resistant multidrug-resistant M. tuberculosis (MIC(90), 0.5 microg/ml) as well as drug-susceptible isolates (MIC(90), 0.06 microg/ml). The anti-tubercle bacilli activity of DC-159a was 4- to 32-fold more potent than those of currently available quinolones. DC-159a also demonstrated the highest activities against clinically important nontuberculous mycobacteria.

Entities: Chemical Species

Mesh：

Substances：

Year: 2010 PMID： 20368403 PMCID： PMC2876381 DOI： 10.1128/AAC.01545-09

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. Minimising moxifloxacin resistance with tuberculosis.

Authors: Karl Drlica; Xilin Zhao; Barry Kreiswirth
Journal: Lancet Infect Dis Date: 2008-05 Impact factor: 25.071

2. Activity of moxifloxacin against mycobacteria.

Authors: S H Gillespie; O Billington
Journal: J Antimicrob Chemother Date: 1999-09 Impact factor: 5.790

3. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.

Authors: Barbara A Brown-Elliott; Richard J Wallace; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal: Antimicrob Agents Chemother Date: 2002-10 Impact factor: 5.191

4. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.

Authors: I Guillemin; V Jarlier; E Cambau
Journal: Antimicrob Agents Chemother Date: 1998-08 Impact factor: 5.191

5. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Authors: Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Richard J O'Brien; Andrew N Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal: Am J Respir Crit Care Med Date: 2003-10-24 Impact factor: 21.405

6. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

Authors: R Rustomjee; C Lienhardt; T Kanyok; G R Davies; J Levin; T Mthiyane; C Reddy; A W Sturm; F A Sirgel; J Allen; D J Coleman; B Fourie; D A Mitchison
Journal: Int J Tuberc Lung Dis Date: 2008-02 Impact factor: 2.373

7. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.

Authors: Michael Cynamon; Mary R Sklaney; Carolyn Shoen
Journal: J Antimicrob Chemother Date: 2007-06-08 Impact factor: 5.790

8. In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.

Authors: Catherine Clark; Kathy Smith; Lois Ednie; Tatiana Bogdanovich; Bonifacio Dewasse; Pamela McGhee; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2007-10-15 Impact factor: 5.191

9. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.

Authors: Kazuki Hoshino; Kazue Inoue; Yoichi Murakami; Yuichi Kurosaka; Kenji Namba; Yoshinori Kashimoto; Saori Uoyama; Ryo Okumura; Saito Higuchi; Tsuyoshi Otani
Journal: Antimicrob Agents Chemother Date: 2007-10-15 Impact factor: 5.191

Review 10. Fluoroquinolones as chemotherapeutics against mycobacterial infections.

Authors: Michael R Jacobs
Journal: Curr Pharm Des Date: 2004 Impact factor: 3.116

13 in total

1. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Authors: Zahoor Ahmad; Austin Minkowski; Charles A Peloquin; Kathy N Williams; Khisimuzi E Mdluli; Jacques H Grosset; Eric L Nuermberger
Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191

Review 2. New drugs and regimens for treatment of TB.

Authors: Eric Leibert; William N Rom
Journal: Expert Rev Anti Infect Ther Date: 2010-07 Impact factor: 5.091

3. Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone.

Authors: Jun-ichiro Sekiguchi; Areeya Disratthakit; Shinji Maeda; Norio Doi
Journal: Antimicrob Agents Chemother Date: 2011-05-09 Impact factor: 5.191

4. Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity.

Authors: Nicholas D Franz; Juan Manuel Belardinelli; Michael A Kaminski; Louis C Dunn; Vinicius Calado Nogueira de Moura; Michael A Blaha; Dan D Truong; Wei Li; Mary Jackson; E Jeffrey North
Journal: Bioorg Med Chem Date: 2017-05-08 Impact factor: 3.641

5. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.

Authors: Guy E Thwaites; Sujata M Bhavnani; Tran Thi Hong Chau; Jeffrey P Hammel; M Estée Török; Scott A Van Wart; Pham Phuong Mai; Daniel K Reynolds; Maxine Caws; Nguyen Thi Dung; Tran Tinh Hien; Robert Kulawy; Jeremy Farrar; Paul G Ambrose
Journal: Antimicrob Agents Chemother Date: 2011-04-18 Impact factor: 5.191

6. Mycobacterium abscessus drug discovery using machine learning.

Authors: Alan A Schmalstig; Kimberley M Zorn; Sebastian Murcia; Andrew Robinson; Svetlana Savina; Elena Komarova; Vadim Makarov; Miriam Braunstein; Sean Ekins
Journal: Tuberculosis (Edinb) Date: 2022-01-20 Impact factor: 3.131

7. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.

Authors: Areeya Disratthakit; Therdsak Prammananan; Chanwit Tribuddharat; Iyarit Thaipisuttikul; Norio Doi; Manoon Leechawengwongs; Angkana Chaiprasert
Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191

Review 8. NTM drug discovery: status, gaps and the way forward.

Authors: Mu-Lu Wu; Dinah B Aziz; Véronique Dartois; Thomas Dick
Journal: Drug Discov Today Date: 2018-04-07 Impact factor: 7.851

Review 9. Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities.

Authors: Anna Egorova; Mary Jackson; Victor Gavrilyuk; Vadim Makarov
Journal: Med Res Rev Date: 2021-03-01 Impact factor: 12.388

Review 10. Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors: Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal: Pharmaceuticals (Basel) Date: 2021-05-13